0000000000348750

AUTHOR

M.j. Blanchard

showing 1 related works from this author

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.

2020

[Purpose] Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next-generation flow (NGF) cytometry. Thus, we aimed to determine the applicability and sensitivity of the flow MRD-negative criterion defined by the International Myeloma Working Group (IMWG).

OncologyMaleCancer Researchmedicine.medical_specialtyNeoplasm ResidualDiseaseResidualTHERAPYDexamethasoneFlow cytometryBortezomib03 medical and health sciences0302 clinical medicineInternal medicinehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansMeaning (existential)Longitudinal StudiesLenalidomideMultiple myeloma030304 developmental biologyCONSOLIDATIONRandomized Controlled Trials as Topic0303 health sciencesCOMPLETE RESPONSEmedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseFlow Cytometry3. Good healthClinical trialPROGNOSTIC VALUEbody regionsMRDOncologyClinical Trials Phase III as Topic030220 oncology & carcinogenesisFemaleSTEM-CELL TRANSPLANTbusinessMultiple MyelomaDARATUMUMABJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct